Truemeds
PrivateLast Round
Series C
Aug 11, 2025
Est. Valuation
$400M
Total Funding Raised
$112.49M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Truemeds operates in Healthcare & Life Sciences and is based in Mumbai. Its latest recorded funding round was a Series C round in August 2025.
Truemeds is a healthtech company that operates an e-pharmacy and telehealth platform providing affordable, clinically equivalent generic alternatives to branded medications.
Sector
Healthcare & Life Sciences
Verticals
E-commerce, Telemedicine, D2C Brands, Pharma Supply Chain
Business Model
B2C
Customer Profile
Marketplace Commission, Hardware Sales, Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Truemeds Comparables
Compare Truemeds with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PharmEasy | 87% | |
| PlatinumRx | 86% | |
| Zeno Health | 85% |
For institutional investors. Book with your work email.
Truemeds Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 11, 2025 | ||||
| Series B | Apr 26, 2022 | ||||
| Series A | Jun 8, 2021 | ||||
| Seed | May 22, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Truemeds Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IAN Group | Series B, Series A |
| Peak XV Partners | Series C |
| Info Edge Ventures | Series B, Series C, Series A, Seed |
| Inception Studio Capital | Series B |
| WestBridge Capital | Series C, Series B |
| Asha Ventures | Series B, Series A |
| Accel | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
Actor Paresh Rawal featured in upcoming campaign.
- Jan 1, 2026
Achieved 3.6x growth in revenue over two years.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenueSep 10, 2026
Truemeds generates an estimated $179M in annual revenue in 2025.
- acquiresAug 31, 2026
Truemeds is reportedly in advanced talks to acquire DealShare through a share-swap transaction that could value DealShare at a little over $90 Mn.
For institutional investors. Book with your work email.
Truemeds Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Truemeds's valuation, stock price, and market status.
Is Truemeds a public or private company?
Truemeds is a private company.
What is the current stock price of Truemeds?
Truemeds is a private company, so its shares have no public market price. Caplight tracks Truemeds's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Truemeds worth (valuation)?
Truemeds's valuation is estimated at $400.0M based on funding round data.
Can I buy Truemeds stock?
Truemeds shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Truemeds's last funding round?
Truemeds's most recent funding round was Series C on August 11, 2025.
Who are the main investors in Truemeds?
Key investors in Truemeds include Peak XV Partners, Info Edge Ventures, WestBridge Capital, Accel.
Will Truemeds IPO soon?
No public IPO plans have been announced for Truemeds.
How can I track Truemeds secondary market activity?
Caplight tracks bids, offers, and trades in Truemeds's shares on secondary markets.